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Abstract
Background: Infants infected during pregnancy or while breastfeeding requires early HIV diagnosis at 6 weeks after
birth to identify HIV infection and timely treatment. The objective of this work was to determine the prevalence and
associated risk factors of HIV among HIV exposed infants in the Tigray regional state, Northern Ethiopia.
Methods: A cross-sectional study was conducted on 350 exposed infants born to HIV seropositive mothers
from September 01 to December 30, 2016. Convenient consecutive sampling technique was employed to enroll
HIV exposed infants from age 6 weeks to 18months attending prevention of mother to child transmission (PMCT)
clinic at Anti Retroviral Therapy (ART) site facility in Tigray, Ethiopia. Sociodemographic data and associated risk factors
were collected using a structured questionnaire. Dried Blood Spot (DBS) samples were collected from each infant and
transported by post to Tigray Health Research Institute to detect HIV infection using real-time Polymerase Chain
Reaction (PCR). Data were entered into EPI Info version 7, exported and analyzed using Statistical Package for Social
Sciences (SPSS) version 22. p-value less than 0.05 was deemed to be statistically significant by Fisher’s exact test.
Results: Three hundred forty infants (175 males, 165 females) met the criteria for selection during the completion of
the study and the overall HIV prevalence was found to be 2.1% (n = 7). The majority of infants were from urban areas
(n = 246, 72.4%). 45.5% (5/11, p = 0.001) infants were without ARV prophylaxis, 60% (3/5, p = 0.001) infants born to
mothers who did not take maternal PMTCT intervention, 43% (3/7, p = 0.001) infants born to mothers who were not
enrolled to ART care, and 6.1% (4/66, p = 0.029) infants of unmarried mothers showed statistically significant difference.
Conclusions: The overall prevalence of HIV among exposed infants was high but lower than the Millennium
Development Goal targets. In order to eliminate the mother to child HIV transmission (MTCT) ARV prophylaxis
in infants must be strengthened, and enrollment of HIV positive pregnant women to PMTCT and ART care
and treatment is needed.
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Background
HIV induced acquired immunodeficiency syndrome (AIDS)
pandemic, has been a major medical and public health
problem globally [1]. According to the World Health
Organization (WHO), an estimated number of 39 million
people have died since the first cases were reported in 1981
[2]. There were approximately 36.7 (34.0–39.8) million
people living with HIV with 2.1 (1.8–2.4) million people be-
coming newly infected in 2015 globally (http://www.unaids.
org/sites/default/files/media_asset/UNAIDS_FactSheet_en.
pdf). Sub-Saharan Africa is the most affected region, with
25.6 (23.1–28.5) million people living with HIV in 2015 and
accounts for almost 70% of the global prevalence (http://
www.unaids.org/sites/default/files/media_asset/UNAIDS_
FactSheet_en.pdf, http://www.who.int/mediacentre/fact-
sheets/fs360/en/). The contribution of children under 15
infected by HIV was 2.6 million with 88% of the cases being
reported from Sub-Saharan Africa (http://www.unaids.org/
sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf,
https://data.unicef.org/wp-content/uploads/2015/12/2015-
Children-Adolescents-and-AIDS-Statistical-Update-Execu-
tive-Summary_244.pdf).
HIV/AIDS epidemic remains one of the important
public health challenges in Ethiopia with the first
cases of HIV and AIDS recognized in 1984 and 1986
respectively [3]. According to the ministry of health
report, the overall estimated national HIV prevalence
was 1.14%, where 769,600 people were living with
HIV and about 15,700 with new HIV infections, while
35,600 AIDS-related deaths were recorded at the end
of 2014 (http://www.afro.who.int/countries/ethiopia).
The prevalence of HIV related estimate for Tigray,
Ethiopia was predicted at 1.8% for 2017 with 6055
cases in the 0–14 age group and 58,742 cases in 15
and above age group (https://www.ephi.gov.et/images/
pictures/download2009/HIV_estimation_and_projec-
tion_for_Ethiopia_2017.pdf ).
The majority of HIV infection among children under
the age of 15 years is due to MTCT which can occur
during pregnancy (in the uterus), labor and delivery, and
breastfeeding (http://www.unaids.org/sites/default/files/
media_asset/UNAIDS_FactSheet_en.pdf, [4]). In the ab-
sence of any intervention, the risk of MTCT during
pregnancy, delivery, and breastfeeding is estimated to be
25 to 45% [5, 6]. Every day there are nearly 1500 new in-
fections in children less than 15 years of age, more than
90% of them occurring in the developing world (http://
www.who.int/hiv/pub/guidelines/paediatric020907.
pdf?ua=1).
HIV infected infants are at increased risk of life-threat-
ening infections such as pneumonia due to Pneumocystis
carinii, Mycobacterium tuberculosis, and nutritional defi-
ciencies and other infections, such as malaria and diar-
rhea, which are often complicated to treat and are the
leading cause of infant mortality in HIV-infected new-
borns and infants [6].
Following the WHO recommendations, in Ethiopia,
the rapid scale-up of ART provides access for preg-
nant women living with HIV and has averted more
than 900,000 new HIV infections among children
since 2009 [5]. A recent report from Tigray Regional
Health Bureau showed that the prevalence of HIV in
exposed infants has declined consistently from a peak
of 9% in 2010/11 to 3.1% in 2014/15 [7]. HIV trans-
mission rate from mother to child at 6 weeks de-
creased from 19% in 2009 to 10% in 2013 with the
final HIV transmission rate from mother to child, in-
cluding during breastfeeding decreasing from 39 to
25% during the same year period. On the contrary,
the number of women (15–49 years old) acquiring
HIV increased by 74% since 2009 which increased
from 4500 in 2009 to 7800 in 2013 (http://www.
unaids.org/sites/default/files/media/documents/
UNAIDS_GlobalplanCountryfactsheet_ethiopia_en.
pdf ). Since 2001, due to the launch of a national
program for PMTCT of HIV infection by the Ethiop-
ian Ministry of Health, the number of facilities with
PMTCT service has reached 1,445 providing ARV
prophylaxis for 10,302 HIV positive pregnant women
and 4,945 exposed infants in 2011 [8]. The prophy-
lactic medication coverage during pregnancy has im-
proved significantly in east and southern Africa but
it is still lower than the 80% target because of lim-
ited healthcare provision during childbirth [8].
To further reduce and prevent the risk of MTCT and
have an AIDS-free generation, early virological testing is
critical for identifying infected infants and to strengthen
the quality of HIV-exposed infant follow-up (http://
www.ilo.org/wcmsp5/groups/public/%2D%2D-ed_pro-
tect/%2D%2D-protrav/%2D%2D-ilo_aids/documents/
legaldocument/wcms_125389.pdf ). Positive HIV anti-
body test in an infant indicates maternal but not neces-
sarily infant HIV infection [9].
National guidelines in Ethiopia recommends that infants
exposed to HIV should be tested by polymerase chain re-
action (PCR) for the detection of viral nucleic acid at 6
weeks of age using dried blood spot samples wherever the
facilities and resources for these assays are available
(http://www.ilo.org/wcmsp5/groups/public/%2D%2D-ed_
protect/%2D%2D-protrav/%2D%2D-ilo_aids/documents/
legaldocument/wcms_125389.pdf). Almost all regional
states in Ethiopia are currently implementing this
programme. However, a scientific study that can clearly
show the prevalence and associated risk factors for ex-
posed infants in Tigray region has not been previously
performed. Hence, the aim of this study was to assess the
prevalence and associated risk factors of HIV among ex-
posed infants in Tigray, Northern Ethiopia.
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Methods
Study area and sample size determination
The study was conducted in 83 public ART site health
facilities in Tigray Regional State, Northern Ethiopia
spread across 54,572.6 sq. km. As projected from the
2007 census, the region has an estimated total popula-
tion of 5,151,998 [10]. The region has 240 public health
facilities serving the population of Tigray and neighbor-
ing areas of other regions. The region has one special-
ized hospital, 15 general hospitals and 224 health
centers; of these 117 are governmental ART site health
institutions. The sample size (n = 350) was determined
using a single population proportion formula. A non-
probability convenient consecutive sampling technique
was employed to enroll the study participants. The num-
ber of study participants in each zone were allocated
proportionally to its size using the proportional alloca-
tion formula.
Study participants and study variables
A cross-sectional study was employed among all HIV
exposed infants from the age of 6 weeks and less than
18months, attending PMTCT clinic in the governmental
ART site health facilities from September 01 to Decem-
ber 30, 2016. Exposed infants who were critically ill and
infants whose parents were unwilling to give their con-
sent were excluded from the study.
Data collection
Clinical data such as CD4 count of the mother during
delivery, infant birth weight and treatment history (eg:
infant ARV prophylaxis at birth, maternal PMTCT inter-
vention) was collected from infant medical record and
mother’s history recording charts using a checklist.
Socio-demographic data such as age, sex, residence, oc-
cupation and other risk factors of the study participants
were collected for each study participants from mothers
using a structured questionnaire by trained personnel.
Laboratory analysis
Sample collection, handling, and transportation Ca-
pillary blood sample (~50ul) was collected from each
HIV-exposed infant via a heel or toe skin prick with
sterile lancet by a trained nurse in the PMTCT clinic
using pre-punch protein Saver 903® cards (Whatman
Ltd., Piscataway, USA), with at least 4 spots in the
same location, which was then be left to dry by put-
ting the card horizontally. The dried cards were
packed individually with desiccant sachets and humid-
ity indicators in each PMTCT clinic at ART site
health facilities until further processing. The speci-
mens were transported to the Tigray health research
institute (testing site) by the post and received within
two to 3 days and processed immediately upon re-
ceipt. If there was an unavoidable delay at the health
facility or in the testing site, cards were stored at 15–
30 °C for less than 12 weeks and 2–8 °C or − 10 °C for
period greater than 12 weeks [11].
Sample processing using DNA PCR Upon the arrival
of sample at Tigray health research institute, it was proc-
essed using a standard procedure. Two spots of DBS
samples (~ 50 μL each) were transferred into a 50ml fal-
con tube with 1.7 mL of bulk lysis buffer; then incubated
for 20 min at room temperature with intermittent gentle
mixing in between 10min. The whole volume was trans-
ferred into a 5 ml reaction vessel: samples and controls
were placed in sample racks with one positive control
(2G31X) and one negative (2G31Z) controls, and re-
agents placed on different rack within the bar-coded re-
action vessels on Abbot EID M2000 sample preparation
(Abbot EID M2000sp, United States of America) auto-
mation for extraction process (Fig. 1).
The Abbott m2000sp then performed the auto method
nucleic acid extraction, washing, and elution. The in-
ternal control (IC) was introduced in the mLysis buffer
before the mLysis buffer was loaded on the Abbott
M2000sp. After the sample extraction was completed,
the amplification reagents (the master mix tube) were
loaded on the Abbott m2000sp. The master mix was
then added to the 96-well Optical Reaction Plate with
the extracted nucleic acids on the Abbott m2000sp and
centrifuged at 3900 rpm using centrifuge (Sigma 2–16,
Germany) for 5 min to avoid bubble and transferred in
to real-time PCR machine (Abbot EID m2000rt, United
States of America) for DNA amplification and detection.
When amplification was completed, Abbott m2000rt an-
alyzed the Real-time PCR data and assigned a qualitative
positive or negative result to each sample. The HIV-1
target sequence that is present at the amplification cycle
is detected by the use of fluorescent-labeled oligonucleo-
tide probes by the Abbott m2000rt instrument. The
probes do not generate signal unless they are specifically
bound to the amplified product.
Quality assurance
Questionnaire was first prepared in English and trans-
lated into Tigrigna (local language). Training was pro-
vided to data collectors on sample collection before
prior to data collection. The collected data were
reviewed for completeness, accuracy, clarity, and
consistency by data collectors and the principal inves-
tigator. A questionnaire was checked and manually
updated if there were incomplete or unrecorded
values, and unlikely responses and laboratory results
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were recorded in the laboratory data result in formats
coded for each participant.
Abbott real-time HIV-1 qualitative controls (high posi-
tive and negative) were used to establish run validity of
the Abbott real-time HIV-1 qualitative assay when used
for the qualitative detection of HIV-1 nucleic acid from
human dried blood spots (DBS) in each batch.
Data analysis and interpretation
Each collected data was labeled using specific patient
codes. The data were entered into Epi Info version
7. Data was then exported and analyzed using Statis-
tical Package for Social Sciences (SPSS) version 22.
Descriptive statistics were computed to summarize
data and result was presented using tables. Polymer-
ase chain reaction results were analyzed using fre-
quency and percentage. Association between
different variables with outcome was analyzed using
Fisher exact test. A p-value less than 0.05 was con-
sidered as statistically significant.
Results
Socio-demographic characteristics of study participants
The response rate of the present study was 97.1% (340/
350). About 143 (42%) of study participants were en-
rolled from hospitals and the remaining 197 (58%) were
from the ART health centers. Among the 340 infants
that participated participant, 175 (51.5%) were males
and the rest females. Majority of HIV exposed infant’s
mothers (n = 234, 68.8%) were in the age range of 25–34
years. More than half of the mothers (n = 211, 62.1%)
were educated at least at the primary level or above and
274 (80.6%) of the mothers were married and 246
(72.4%) belonging to an urban area (Table 1).
The majority, 338 (99.4%) of the exposed infants were
in the age range of 6 weeks to 6 months and were born
(n = 332, 97.6%) in various health institutions in Tigray.
The mean age of infants at sample collection time was
49.9 days (SD + 27.8). Almost all, 337 (99.1%) of the in-
fants were exclusively breastfed, 323 (94.4%) of them
had a normal delivery, 325 (95.6%) had a birth weight of
greater than or equal to 2.5 kg and 329 (96.8%) received
Fig. 1 Workflow in detection of infant HIV infection by PCR
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Table 1 Exposed infant and maternal-related characteristics by HIV positivity among HIV exposed infants in Tigray, Ethiopia, 2016
(n = 340)
Variables Frequency,
[n, %]
HIV status P-
value*Positive, [n, %] Negative, [n, %]
Gender of infant
Male 175 (51.5) 3 (1.7) 172 (98.3)
Female 165 (48.5) 4 (2.4) 161 (97.6) 0.71
Residence
Urban 246 (72.4) 6 (2.4) 240 (97.6)
Rural 94 (27.6) 1 (1.1) 93(98.9) 0.68
Maternal education
Illiterate 129 (37.9) 5 (3.9) 124(96.1)
Primary & above 211 (62.1) 2 (0.9) 209 (99.1) 0.11
Maternal age (in years)
18–24 56 (1.5) 1 (1.8) 55 (98.2)
25–34 234 (68.8) 5 (2.1) 229 (97.9)
35–44 50 (14.7) 1 (2.0) 49 (98) NA
Maternal marital status
Not married 66 (19.4) 4 (6.1) 62 (93.9)
Married 274 (80.6) 3 (1.1) 271 (98.9) 0.029*
Maternal occupation
Housewife 260 (76.5) 1(0.4) 259 (99.6)
Government employee 17 (5) 1 (5.9) 16 (94.1) NA
Self-employed 63 (18.5) 5 (7.9) 58 (92.1)
Infant age at enrolment
6 weeks-6 months 338 (99.4) 7 (2.1) 331 (97.9)
6–18 months 2 (0.6) 0 (0) 2 (100) NA
Place of delivery
Institutional 332 (97.6) 7 (2.1) 325 (97.9)
Home 8 (2.4) 0 (0) 8 (100) NA
Infant Feeding pattern
Exclusive breast-feeding 337 (99.1) 7 (2.1) 330 (97.9)
Formula 2 (0.6) 0 (0) 2 (100)
Mixed feeding 1 (0.3) 0 (0) 1 (100) NA
Mode of delivery
Normal 323 (94.4) 7 (2.2) 316 (97.8)
Cesarean 17 (5.6) 0 (0) 17 (100) NA
Infant birth weight (Kg)
< 2.5 15 (4.4) 0 (0) 15 (100)
≥ 2.5 325 (95.6) 7 (2.2) 318 (97.8) NA
Infant ARV prophylaxis
Not Received 11 (3.2) 5 (45.5) 6 (54.5)
Received 329 (96.8) 2 (0.6) 327 (99.4) 0.001*
Maternal ART enrolment
Enrolled 333 (97.9) 4 (1.2) 329 (98.8)
Not enrolled 7 (2.1) 3 (42.9) 4 (57.1) 0.001*
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ARV prophylaxis (Table 1). In addition, higher propor-
tions 235 (69.1%) of the mothers were taking ‘Option
B+’ (Table 1).
Prevalence of infant HIV using RT PCR
Three hundred and forty HIV-exposed infants were
tested for HIV infection by real-time PCR. This study re-
vealed that the overall prevalence of HIV infection
among exposed infants was 2.1% (n = 7) (Table 1). More-
over, all the 7 HIV-infected infants were from institu-
tional births, exclusively breastfeed and were normal
deliveries in the age group of thier mothers 25–34 years.
Risk factors associated with HIV positivity in HIV exposed
infants
In this study, maternal marital status, ART care enroll-
ment, taking PMTCT intervention and receiving infant
ARV prophylaxis were showed statistically significant
with HIV positivity (Table 1). Higher proportions of HIV
positive infants were from non-married mothers 4
(6.1%) and not being married was a risk factor deemed
to be statistically significant (P = 0.029) for infants con-
tracting HIV. In addition, the proportion of HIV positiv-
ity was higher in infants whose mothers were not
enrolled to ART care than their enrolled counterparts
(6.1% vs. 1.1%) and was statistically significant (P =
0.001) risk factor. The infants who did not receive ARV
prophylaxis had statistically higher proportions of HIV
positivity 45.5%, (p = 0.001). In this study HIV positivity
was higher proportion in infants from urban area than
the rural area but was not a statistically significant risk
factor (p-value = 0.678).
Discussion
The prevalence of HIV infection in this study was 2.1%
(7/340) and comparable to that observed in Brazil
(2.01%) [12]. Our findings were within the global and
national plan to reduce MTCT rates to 5% or less by
2015 [2], (http://pdf.usaid.gov/pdf_docs/PA00JWM5.
pdf ). The findings of the current study were higher than
studies conducted in Ukraine (1.6%) [13] and France
(1.5%) [14]. The difference may be due to high coverage
of PMTCT interventions in developed countries and
limited access, lack of awareness, poor quality of service
and others in resource-limited countries like Ethiopia.
The prevalence in the current study was however; lower
than the study reports from Brazil (11.8%) [15], Kenya
(5%) [16], Malawi (4.1%) [17] and Zambia (6.5%) [18].
The difference in prevalence might be explained due to
the difference to ART and PMCT follow up, awareness
to HIV, policies, and strategies on HIV control and pre-
vention, methodology and sample size.
Prevalence in this study was lower than those con-
ducted in other parts of Ethiopia including Southern
Ethiopia (4.16%) [19], Bishoftu hospital (4.3%) [20],
North West Ethiopia (10%) [21], Jimma (10.9%) [22],
Driedawa (15.7%) [8] and Addis Ababa (32.1%) [23].
These studies showed higher prevalence, as most of
these are retrospective studies their data collection time
were ranging from 2005 to 2013, before the implementa-
tion of successful intervention strategies like Option B+.
Since 2013, Ethiopia is implementing suitable guidelines
such as Option B+ where a lifelong antiretroviral treat-
ment is provided to all pregnant and breastfeeding
women living with HIV regardless of CD4+ count or
WHO clinical stage and Nevirapine to infants in the first
6 weeks of life [24]. In the current time, HIV infection
in exposed infants is decreasing through time due to the
overall efforts are done to prevent new HIV infection in
infants.
Vertical transmission of HIV in infants is a multi-factor-
ial process, which involves factors associated with HIV-1
transmission. In the present study, the prevalence of HIV
was high among infants who did not take antiretroviral
prophylaxis at birth (n = 11, 3.2%), than those who did
take ARV prophylaxis at birth (n = 329, 96.8%) and this
was found to be statistically significant (p < 0.05). Our
findings are in line with studies reported from Driedawa
[8], Malawi [17], Zambia [18], Nigeria [25] and Ukraine
[13]. This result is consistent with the widely scientifically
accepted fact that ARV in infants decreases the risk of
HIV infection [26].
Table 1 Exposed infant and maternal-related characteristics by HIV positivity among HIV exposed infants in Tigray, Ethiopia, 2016
(n = 340) (Continued)
Variables Frequency,
[n, %]
HIV status P-
value*Positive, [n, %] Negative, [n, %]
PMTCT
Option B+ and on ART 335 (69.1) 4 (1.2) 331 (98.8)
None 5 (1.5) 3 (60) 2 (40) 0.001*
Maternal CD4+ count at late pregnancy (cell/mm3)
< 200 13 (3.9) 0 (0) 13 (100)
≥ 200 327 (96.1) 7 (2.1) 320 (97.9) NA
*P-Value < 0.05 indicates significant result by Fisher's exact test
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In addition to infant’s prophylaxis taking maternal
PMTCT intervention was statistically significant in de-
creasing HIV positivity. The finding was agreed with the
study done in North West Ethiopia [21], Amhara [27],
Tanzania [28], Malawi [17], Nigeria [25] and Zambia
[18]. Accordingly, infants who were born to mother who
took Option B+ and already on ART had a lower rate of
HIV positivity (1.2%) than those who born to mother
who didn’t take PMTCT intervention that was (60%).
This is supported by the scientifically accepted idea that
maternal PMTCT interventions decrease the HIV posi-
tivity in exposed infants [29]. The lower prevalence of
HIV (1.2%) in pregnant women was also reported previ-
ously in the Amhara region in Ethiopia, which reported
high prevalence (10.1%) among the infants born to these
mothers [27]. This was due to delayed HIV diagnosis, in-
adequate use of antiretroviral therapy and lack of skilled
delivery, which promotes mother-to-child transmission
of HIV. In the current study the HIV status of HIV posi-
tive mothers enrolled for ART was very low (1.2%, 4/
333) (Table 1). This is due to the improved coverage at
public health facilities responsible for PMTCT and also
low number of sample size.
The HIV positivity was high (10.1%) among HIV exposed
infants of mothers with the age range of 25–34 which is con-
sistent with a study from Amhara, Ethiopia [27]. In addition,
HIV positivity was high in mothers with CD4+count
>200cell/mm3compared to mothers with CD4+count of <
200cell/mm3 in our study. In Zimbabwe [30] it was observed
that maternal CD4+cell count less than 200 cell/mm3 was
significantly associated with infant HIV positivity. But there
are other contradictory to reports from France [14], Brazil
[15] and Malawi [17]which show no significant association.
In the current study as we observe maternal CD4+ count of
>200cell/mm3 in mothers that are HIV positive, we can con-
clude that infection can be transmitted from these mothers
to the exposed infants. This may be supported with a conclu-
sion from a study with effective antiretroviral coverage; ma-
ternal CD4 count does not affect the HIV positivity [31].
Our result showed that due to many national and inter-
national efforts towards PMTCTand HIV infection, the HIV
prevalence among exposed infants is decreasing from time
to time.
Conclusion
The overall prevalence of HIV among exposed infants was
2.1%, which is still high prevalence but lower than the Millen-
nium Development Goal (MDG) targets. We observed that,
HIV positivity was higher in infants who did not take ARV
prophylaxis and whose mothers did not enroll to ART care
and follow up and infants of mothers who did not take
PMTCT interventions during pregnancy or childbirth. There-
fore, in order to eliminate the MTCT, increasing antenatal
HIV screening and linking HIV positive pregnant women to
PMTCT and ART care and providing appropriate ARV
prophylaxis to infants must be done efficiently. Strengthening
national monitoring surveillance, coverage, and quality of
HIV interventions in mother and child health (MCH) services
is important for the PMTCT program.
The prevalence of HIV among infants born from sero-
positive mothers is reduced to the meaningful number
(< 5%) because of the appropriate measures taken for re-
ducing the transmission of HIV from mothers to infants.
But, because a significant number of infants from sero-
positive mothers are still infected. We recommend:
Strengthening of the PMTCT of HIV programme, in-
creasing antenatal HIV screening and linking it to care
and treatment of HIV positive mothers to obtain zero
infant HIV prevalence in the region. Infant prophylaxis
and maternal PMTCT interventions should be provided
to all exposed infants and mothers based on the guide-
lines by the health institutions. ART centers in every
health institutes and Tigray regional health bureau HIV
regional offices should work together to enroll all HIV
seropositive mothers to ART care and support which will
help to decrease the prevalence of HIV in Tigray even
further.
Limitation of the study
We were unable to see the independent effect of variables
on the outcome so further studies taking an adequate
period of time and on larger sample size is required.
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